Aimovig (erenumab-aooe) / Amgen, Novartis - LARVOL DELTA

Real-World Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies in the Prevention of High-Frequency Episodic and Chronic Migraine in Romania-A Multicenter Retrospective Observational Study. (PubMed, Biomedicines) - " We conducted a multicenter retrospective observational cohort study including 113 adults with HFEM (n = 38) or CM (n = 75) who initiated treatment with galcanezumab, erenumab, fremanezumab, or eptinezumab at specialized headache centers in Romania. The treatment was generally well-tolerated, with predominantly non-serious adverse events and a low rate of discontinuation due to adverse events. These findings provide real-world evidence from Romania and support further prospective evaluation of the long-term effectiveness and safety of anti-CGRP monoclonal antibodies."

Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

Efficacy and Safety of Erenumab in Preventive and Therapeutic Treatment of Patients Suffering from Migraine. (PubMed, Ann Afr Med) - "Erenumab subcutaneous once monthly was the most efficacious treatment regimen and was not associated with a significant risk for treatment related adverse events."

Journal • CNS Disorders • Migraine • Pain

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Some drugs for migraine prevention. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

A multidisciplinary multicentric approach to the identification of predictive biomarkers of response to erenumab - the protocol of the phase 4, European, open-label controlled trial of the BIOMIGA project. (PubMed, Front Neurol) - P | "By combining a comprehensive multimodal profiling with a real-world, multicentre cohort of patients treated with erenumab, the study provides a framework for identifying robust biomarkers of treatment response and lays the foundation for truly individualised migraine prevention strategies. ClinicalTrials.gov, identifier NCT04503083."

Biomarker • Journal • P4 data • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Headache) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Neurology) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • Review • CNS Disorders • Migraine • Pain

New Migraine Guidelines Expand Treatment Options For Migraine Prevention (RTTNews) - "The guidelines discuss how preventive medicines are different from medicines used to treat a migraine attack after it starts...The new guidelines recommend atogepant, erenumab, fremanezumab, galcanezumab, and eptinezumab as first-choice medicines for preventing migraine. These medicines are given in different ways...For people with episodic migraine, meaning migraine occurring on fewer than 15 days a month, the treatments with the strongest evidence of effectiveness include atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, propranolol, topiramate, and valproate....Botox is also an option for chronic migraine."

Clinical guideline • Migraine

Real-world short-term effectiveness of erenumab after single versus multiple prior preventive treatment failures. (PubMed, BMC Neurol) - "Short-term effectiveness of erenumab was comparable in patients with no more than one versus multiple prior preventive treatment failures, suggesting that treatment response is not solely dependent on the number of previous preventive treatment failures. These findings should be interpreted in light of the retrospective single-center design and the limited sample size, which resulted in relatively wide confidence intervals."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

Tracking migraine outcomes over time by age and monoclonal antibody type: a retrospective, single-center, real-world study. (PubMed, Front Neurol) - "We conducted a retrospective, single-center observational study including 453 adults with episodic or chronic migraine treated with erenumab, galcanezumab, fremanezumab, or eptinezumab between November 2018 and April 2026. In real-world clinical practice, CGRP mAbs demonstrate comparable and durable effectiveness across age groups. Subtle long-term differences between agents may emerge, particularly for multidimensional clinical improvement, supporting individualized treatment selection."

Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study. (PubMed, J Ultrason) - "Additionally, a subanalysis revealed no significant differences based on the specific monoclonal antibody (erenumab, fremanezumab, or galcanezumab) or clinical response status (responders versus non-responders). Our findings suggest that treatment with anti-CGRP monoclonal antibodies is not associated with a BHI indicative of increased cerebrovascular risk. Notably, this is the first study to include galcanezumab and fremanezumab in the evaluation of cerebrovascular risk using ultrasound, highlighting TCCD ultrasonography as a practical and non-invasive tool for the assessment of cerebrovascular reactivity in migraine."

Journal • CNS Disorders • Migraine • Pain

Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. (PubMed, Cephalalgia) - "Adults with migraine initiating CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) were compared with initiators of onabotulinumtoxinA from January 2018 through September 2023. Several secondary, subgroup, and supportive analyses remained inconclusive for non-inferiority. Larger adequately powered comparative safety studies are needed."

Clinical • Journal • Real-world evidence • Retrospective data • Cardiovascular • CNS Disorders • Ischemic stroke • Migraine • Musculoskeletal Diseases • Orthopedics • Pain

Screening Trial for Pain Relief in Schwannomatosis (STARFISH) (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Massachusetts General Hospital | Trial completion date: Nov 2027 ➔ Nov 2028 | Trial primary completion date: Nov 2026 ➔ Nov 2027

Trial completion date • Trial primary completion date • Brain Cancer • Pain • Solid Tumor

Association of Serum hs-CRP and TNF-α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine (REFORM) Study. (PubMed, Eur J Neurol) - "Peripheral inflammatory biomarkers such as hs-CRP and TNF-α neither predict response nor change meaningfully during CGRP-receptor blockade. These results suggest broadly applied inflammatory markers do not capture treatment-relevant biology and highlight the need for mechanism-specific biomarkers to advance personalized migraine therapy."

Biomarker • Journal • Observational data • CNS Disorders • Inflammation • Migraine • Oncology • Pain • CRP • TNFA

Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience. (PubMed, Front Neurol) - "A total of 80 patients (62 chronic and 18 episodic migraine) received Erenumab, Galcanezumab, or Rimegepant. It also highlights important challenges related to treatment access and adherence. Findings should be interpreted in the context of observational design of the study, and further controlled studies are warranted."

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study. (PubMed, Cephalalgia) - "We aimed to evaluate early functional outcomes in daily and school activities, as well as headache-related outcomes after initiating CGRP mAb therapy in Japanese adolescents with migraine.MethodsThis single-center retrospective cohort study included patients aged 15-17 years who received CGRP mAb therapy (galcanezumab, fremanezumab or erenumab) for migraine between May 2021 and July 2025. Safety and tolerability findings are particularly notable given the limited evidence in this age group. Further prospective controlled studies are warranted to validate these findings and to identify predictors of early functional response."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

Aimovig: Regulatory submission for pediatric migraine in 2028 (Novartis) - Q2 2026 Results

Filing • CNS Disorders • Migraine • Pain

Epidemiology, Safety of Dilation, and Medication-Associated Risk of Acute Angle-Closure Crisis in the United States. (PubMed, Am J Ophthalmol) - "AACC following pharmacologic dilation was rare and occurred predominantly among patients with anatomical risk factors, supporting the safety of dilation in routine clinical care. Medication-associated risk signals were observed across commonly prescribed drugs at the population level, including previously unreported associations, highlighting the importance of proactive ocular risk assessment and medication reconciliation in anatomically predisposed patients. Novel medication associations with calcium channel blockers, CGRP monoclonal antibodies, and PCSK9 inhibitors warrant further investigation."

Journal • Glaucoma • Ophthalmology

Iatrogenic harm in paediatric and adolescent populations of patients with migraine: A systematic review with meta-analysis. (PubMed, Cephalalgia) - "The most used compounds were topiramate (22 subsamples), propranolol and sodium valproate (six subsamples)...Erenumab showed the highest rate of AEs, most likely due to the higher-precision detection typical of a randomized controlled trial, and cinnarizine the lowest. In total, 53 different AEs were reported, most frequently drowsiness, anorexia, fatigue and paraesthesia.ConclusionsIn accordance with the results of this systematic review with a meta-analysis, clinicians should consider that 30% of the paediatric patients with migraine will report some AEs from prevention treatment. The information on the safety profile is essential for clinicians in evaluating the choice of a specific therapy, making a better risk/benefit ratio evaluation for each single patient, which is crucial in consideration of the inconsistent efficacy profiles of preventive medications, with the exception of topiramate, in this population."

Clinical • Journal • Retrospective data • Review • Anorexia • CNS Disorders • Fatigue • Migraine • Pain • Pediatrics

Stroke risk associated with CGRP pathway inhibitors in adults with migraine: Systematic review and meta-analysis of randomized trials (AHS 2026) - "Trials evaluated eptinezumab, erenumab, fremanezumab, and galcanezumab, with follow-up ranging from 12 to 56 weeks. Available randomized evidence does not suggest an increased risk of stroke or TIA with CGRP pathway inhibitors in adults with migraine. Although longer follow-up and real-world data are needed—particularly in patients with elevated baseline vascular risk—these findings provide reassuring cerebrovascular safety data supporting continued clinical use."

Retrospective data • Review • CNS Disorders • Migraine • Pain

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. (PubMed, Headache) - "Commercial launch was the most consistent driver of public search interest in CGRP-targeting therapies. Media exposure produced additional increases in selected cases, whereas regulatory approvals and clinical trial publications had limited measurable impact. These findings underscore the dominant role of commercial and consumer-facing communication in shaping public awareness of new migraine treatments."

Journal • CNS Disorders • Migraine • Pain

Characteristics of Migraine Patients Who Successfully Discontinued Anti-CGRP Monoclonal Antibodies: A Single-Center Retrospective Study (EAN 2026) - " The anti-CGRP mAbs administered included galcanezumab ( n = 96), erenumab ( n = 66), and fremanezumab ( n = 95). Successful discontinuation of anti-CGRP mAbs was independently associated with fewer baseline MMDs and absence of MOH. Early initiation of preventive therapy—before high frequency and medication overuse develop—may enhance the likelihood of successful treatment withdrawal, supporting a treat-to-target strategy aimed at eventual treatment graduation."

Retrospective data • CNS Disorders • Migraine

Beyond Triptans in menstrual migraine: the emerging role of CGRP-Targeted therapies. (PubMed, Expert Opin Emerg Drugs) - "Among available options, gepants offer the greatest potential due to their flexibility for both acute and short-term preventive use. Future research should focus on time-specific treatment strategies and a broader understanding of the underlying biology, including the role of additional neuropeptides."

Journal • Review • CNS Disorders • Migraine • Pain

Digital milestones and public interest in CGRP-targeting migraine therapies: An infodemiology study in the United States (AHS 2026) - "Seven FDA-approved preventive therapies were analyzed: erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant, and ubrogepant. In the United States, commercial launches and targeted media exposure are the dominant drivers of public interest in CGRP-targeting therapies, while regulatory approvals and trial publications have limited impact. These findings highlight outsized influence of market entry and consumer-facing media on awareness of CGRP-targeting therapies, underscoring opportunities to strengthen communication around scientific and regulatory milestones. Public search interest in CGRP-therapies in the United States (2017–2025)."

CNS Disorders • Migraine • Pain

CGRP-Targeting Therapies in Vestibular Migraine: A Synthesis of Observational Evidence with Direction-of-Effect Analysis. (PubMed, Med Sci (Basel)) - "CGRP monoclonal antibodies show a consistent direction of benefit for vestibular symptoms, migraine days, and dizziness handicap in observational VM studies, with a favorable safety profile. However, the absence of RCTs, small samples, lack of control groups, and heterogeneity preclude definitive conclusions. This synthesis highlights a critical evidence gap. Adequately powered, double-blind, placebo-controlled RCTs of CGRP-targeting therapies (both monoclonal antibodies and gepants) are urgently needed."

Clinical • Journal • Review • CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo